Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Operating Expenses (2016 - 2025)

Northwest Biotherapeutics' Operating Expenses history spans 16 years, with the latest figure at $14.2 million for Q4 2025.

  • Quarterly results put Operating Expenses at $14.2 million for Q4 2025, down 24.31% from a year ago — trailing twelve months through Dec 2025 was $61.3 million (down 9.72% YoY), and the annual figure for FY2025 was $61.3 million, down 9.72%.
  • Operating Expenses for Q4 2025 was $14.2 million at Northwest Biotherapeutics, down from $14.5 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $21.6 million in Q2 2022 to a low of $10.4 million in Q3 2021.
  • The 5-year median for Operating Expenses is $15.0 million (2024), against an average of $15.5 million.
  • Peak annual rise in Operating Expenses hit 135.74% in 2021, while the deepest fall reached 78.38% in 2021.
  • Year by year, Operating Expenses stood at $10.7 million in 2021, then surged by 75.86% to $18.8 million in 2022, then dropped by 16.98% to $15.6 million in 2023, then rose by 20.16% to $18.7 million in 2024, then decreased by 24.31% to $14.2 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $14.2 million, $14.5 million, and $14.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.